国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

未开盘 07-30 16:08:22

17.650

-0.050

-0.28%

最高17.880	最低17.300	成交量382.62万
今开17.800	昨收17.700	日振幅3.28%
总市值550.86亿	流通市值236.83亿	总股本31.21亿
成交额6,744万	换手率0.29%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":17.65,"timestamp":1785398902002,"preClose":17.7,"halted":0,"volume":3826214,"delay":0,"changeRate":-0.002824858757062187,"floatShares":1341810740,"shares":3121000000,"eps":2.6621950492564475,"marketStatus":"未开盘","change":-0.05,"latestTime":"07-30 16:08:22","open":17.8,"high":17.88,"low":17.3,"amount":67437400,"amplitude":0.032768,"askPrice":17.65,"askSize":53200,"bidPrice":17.64,"bidSize":5600,"shortable":3,"etf":0,"ttmEps":2.6372576055876262,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":0,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":17.7,"dividendRate":0.044793,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":0.8983094086374324,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.2922,"impliedVolPercentile":0.6367},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"2653527497","title":"贝莱德减持国药控股(01099)156.4万股 每股作价17.357港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653527497","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653527497?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:18","pubTimestamp":1784719092,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月16日，贝莱德减持国药控股(01099)156.4万股，每股作价17.357港元，总金额约为2714.63万港元。减持后最新持股数目约为1.33亿股，最新持股比例为9.91%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B42XCP33.USD","IE00B3PB1722.GBP","LU0640798160.USD","BK4567","LU0070302665.USD","LU0130102774.USD","EWH","LU0772969993.USD","BK4535","BLK","LU1366333091.USD","LU1989771016.USD","BK4135","LU0742537680.HKD","LU1988902786.USD","BK4504","LU0640476718.USD","LU1074936037.SGD","IE00BGHQF631.EUR","IE00BDGV0183.EUR","LU1481011911.USD","LU1115378108.SGD","BK1500","LU2430703251.USD","IE00BVYPNW00.USD","LU2592432038.USD","LU1064131342.USD","IE00BVYPNV92.GBP","LU0648001328.SGD","LU0208291251.USD","BK4588","BK4533","BK1197","BK4534","LU1509826696.USD","LU0157215616.USD","LU2430703095.HKD","IE00B3QW5Z07.USD","LU0320765489.SGD","FDFF","LU2430703178.SGD","LU2264538146.SGD","01099","LU1670627923.USD","LU2505996509.AUD","BK4581","BK4585","LU1291159041.SGD","LU1599440770.SGD","LU2505996681.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652475019","title":"【特约大V】邓声兴：美通胀难降温，恒指短线或受压回调","url":"https://stock-news.laohu8.com/highlight/detail?id=2652475019","media":"金吾财讯","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652475019?lang=zh_cn&edition=full","pubTime":"2026-07-17 09:41","pubTimestamp":1784252478,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒指周四 收市报25008点，升327点或1.33%。大市全日成交3228元。国指升133点或1.63%，报8318点；科指涨93点或1.98%，报4834点。澜起科技传出涉及操控价格行为，其在南韩的办事处遭搜查，股价泻23%，报278.6元。高盛回吐4.9%，为跌幅最大道指成份股。Nike反弹4.2%，为表现最强道指成份股。美通胀难降温，恒指短线或受压回调。的进口总代上市达成战略合作，进一步印证集团在创新药进口分销领域的不可替代性。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/NGExMWIwZjY5YWMzZDJiYjI3NzU4NjU1MjcxMDI5NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NGExMWIwZjY5YWMzZDJiYjI3NzU4NjU1MjcxMDI5NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986112","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0593848301.USD","SGXZ62798434.SGD","LU1023057109.AUD","09115","LU0164865239.USD","LU0307460666.USD","LU0501845795.SGD","LU0327786744.USD","LU0823426480.USD","LU0039217434.USD","LU0359201885.HKD","LU1880383440.USD","09992","LU0871576103.HKD","BK1224","03037","LU0531971595.HKD","SG9999002950.SGD","LU1770036033.HKD","07300","LU0164880469.USD","LU0211977185.USD","LU1960683339.HKD","LU0231483743.USD","HSI","MCHmain","LU0588546209.SGD","82800","LU1880383366.USD","LU1115378108.SGD","LU0149721374.USD","LU0067412154.USD","LU0359202008.SGD","LU0345776255.USD","BK1197","LU0348766576.USD","LU1152091754.HKD","PMRTY","LU0611395673.USD","LU1008478684.HKD","LU0499858602.USD","LU0880133367.SGD","LU1481107354.HKD","LU1807302812.USD","LU2543165471.USD","BK1515","LU0572944931.SGD","07500","SG9999001069.SGD","LU0072913022.USD","IE0034224299.USD","02833","SGXZ86797644.SGD","LU0499858438.USD","83115","LU0345775950.USD","LU0348767384.USD","LU0640798160.USD","02800","06809","LU0359201612.USD","LU1152091168.USD","03419","SHTDY","03115","688008","HSTECH","BK1163","LU1993786604.SGD","01099","513600","07200","LU0823426308.USD","BK1500","HHImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650903903","title":"大和：降国药控股(01099)评级至“持有” 目标价降至18港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650903903","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650903903?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:17","pubTimestamp":1783646257,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，国药控股(01099)收入已开始企稳，但尚未出现明确的反弹时间表。2026年零售药房收入指引同比双位数增长。评级由“跑赢大市”降至“持有”，将目标价由21港元下调至18港元。料2026至2028年每股盈利分别同比增4.5%、5.6%及8.5%，较市场预期低3%至6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649629368","title":"摩根大通减持国药控股(01099)约87.41万股 每股作价16.0054港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649629368","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649629368?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:34","pubTimestamp":1783337695,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月30日，摩根大通减持国药控股(01099)87.4052万股，每股作价16.0054港元，总金额约为1398.96万港元。减持后最新持股数目约为8011.23万股，最新持股比例为5.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FTXO","IXG","LU2023250504.SGD","IE00BLSP4452.SGD","PGF","IE00B1XK9C88.USD","LU2211815571.USD","IYF","IE00BJTD4N35.SGD","BK4516","LU2106854487.HKD","UYG","LU0868494708.USD","IE00BDRTCR15.USD","LU1974910355.USD","BK1500","JPMO","IE00BLSP4239.USD","IYG","LU1261432733.SGD","LU0683600562.USD","LU0234572021.USD","BK4504","EWH","LU1894683348.USD","LU0859254822.USD","LU0211326839.USD","KBWB","LU0170899867.USD","LU0265550946.USD","LU0106261372.USD","LU0964807845.USD","LU0211331839.USD","LU1629891620.HKD","LU1145028129.USD","LU1366192091.USD","01099","FNCL","LU1064131342.USD","XLF","JPX","BK4533","LU0187121727.USD","JPO","LU2746668461.USD","BK4534","IE0034235295.USD","IE00BZ1G4Q59.USD","VFH","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176559377","title":"国药控股6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1176559377","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176559377?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:09","pubTimestamp":1783328964,"startTime":"0","endTime":"0","summary":"国药控股于2026年7月6日发布2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司股本结构保持稳定，未发生新增发行、购回或注销等变动。报告期内，未见任何股份期权或其他股权激励计划变动，也无库藏股、回购或注销情况。公告同时确认，公司已符合香港联交所公开持股量要求。该公告由公司秘书吴壹建签署。公司强调将持续遵守香港联交所《上市规则》及相关法律法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130440961","title":"异动解读｜国药控股盘中上涨3.17%，密集签署创新药战略合作协议提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1130440961","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130440961?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:11","pubTimestamp":1783303896,"startTime":"0","endTime":"0","summary":"7月6日，国药控股盘中上涨3.17%，报17.27港元，成交额2048.21万港元。消息面上，国药控股近期密集签署多项战略合作协议。此外，中国中信金融资产管理于6月26日以每股15.86港元增持366.24万股，持股比例升至5.01%，释放机构看好信号。系列合作协议强化了公司在创新药分销领域的竞争壁垒，叠加机构资金持续流入，共同提振市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174587614","title":"异动解读｜国药控股盘中上涨3.04%，除净后技术性修复叠加战略合作催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1174587614","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174587614?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:30","pubTimestamp":1782703822,"startTime":"0","endTime":"0","summary":"6月29日，国药控股盘中上涨3.04%，报16.27港元，成交额3831.24万港元。消息面上，公司6月23日除净后股价经历调整，当前呈现技术性修复。近期公司与东阳光药签署战略合作协议，双方将深度整合流通与创新产品资源，加速创新药市场覆盖。此外，公司此前股东大会已批准不超过已发行H股总数10%的回购授权，为股价提供支撑。末期股息每股0.69元人民币将于8月18日派发，权益记录日为6月30日。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148953054","title":"贝莱德在国药控股H股多头仓位下降，港交所数据显示6月22日降至9.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148953054","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148953054?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:44","pubTimestamp":1782467055,"startTime":"0","endTime":"0","summary":"根据香港交易所披露的最新信息，全球资产管理巨头贝莱德在国药控股H股的多头持仓比例出现下降。数据显示，截至6月22日，其持股比例已从之前的10.19%降至9.63%。这一变动反映了机构投资者对相关持仓的调整，可能受到市场环境、公司基本面或投资策略变化的影响。持仓比例的细微调整往往引发市场关注，投资者可据此观察资金流向及机构态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","LU0640798160.USD","BK1500","BK1515","LU1115378108.SGD","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645000919","title":"国药控股与东阳光药签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2645000919","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645000919?lang=zh_cn&edition=full","pubTime":"2026-06-23 13:28","pubTimestamp":1782192485,"startTime":"0","endTime":"0","summary":"【国药控股与东阳光药签署战略合作协议】据国药控股消息，近日，国药控股与东阳光药战略合作签约仪式在湖北宜都举行。双方将以患者需求为核心，深度整合流通资源与创新产品资源，加速东阳光药创新药的市场覆盖与普及落地，进一步拓宽优质药品的触达范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606233779560422.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606233779560422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0640798160.USD","BK1191","BK1515","06887","LU1115378108.SGD","01099","BK1197","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644709644","title":"国药控股(01099)将于8月18日派发末期股息每股0.69元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644709644","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644709644?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:07","pubTimestamp":1781773645,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布公告，该公司将于2026年8月18日派发末期股息每股0.69元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1115378108.SGD","VIG","BK1500","BK1197","BK4585","BK4588","01099","BK1515","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109415270","title":"国药控股宣派末期股息每股0.69元，8月18日前派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1109415270","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109415270?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:07","pubTimestamp":1781773636,"startTime":"0","endTime":"0","summary":"国药控股宣布，2025年度末期股息方案已于6月18日举行的股东周年大会上获得批准，每股派发末期股息人民币0.69元(含税)，派息日不迟于2026年8月18日。内资股股东及通过港股通持有公司H股的投资者，股息将以人民币派付；其他H股股东的股息将按人民币兑港元平均汇率折算，以每股0.79港元(含税)派付。股权登记日为2026年6月30日，凡当日名列公司股东名册的股东均有权收取股息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药控股宣派末期股息每股0.69元，8月18日前派发","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193784446","title":"国药控股宣派末期股息每股0.69元人民币，派息日8月18日","url":"https://stock-news.laohu8.com/highlight/detail?id=1193784446","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193784446?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:06","pubTimestamp":1781773608,"startTime":"0","endTime":"0","summary":"国药控股发布末期股息更新公告，进一步明确港元派息金额及汇率。公司宣派截至2025年12月31日止年度的末期普通股息，每股派息0.69元人民币，折算为每股0.79港元，汇率按1人民币兑1.15港元计算。此次股息已获股东批准，除净日为2026年6月23日，递交股份过户文件的最后时限为6月24日16:30，暂停办理股份过户登记手续的日期为6月25日至6月30日，权益记录日为6月30日，股息派发日为2026年8月18日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药控股宣派末期股息每股0.69元人民币，派息日8月18日","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644773208","title":"【券商聚焦】中信建投：生物制品板块跟随医药行业整体回调 考虑与资金因素有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2644773208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644773208?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:26","pubTimestamp":1781745972,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究认为：1）中药：板块本周跑赢大盘及医药指数。市场关注呼吸道疾病发病率、基药目录等进展；除此市场持续关注“四同药品”价格专项治理、中成药集采等外部政策环境变化等带来的影响。2）生物制品：板块本周跑输医药指数及大盘。本周板块跟随医药行业整体回调，考虑主要与资金因素有关。3）医药商业：板块本周跑输申万医药，跑赢大盘。药店板块主要关注5月同店数据；流通板块关注院内合规及红利标的。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004311.SGD","LU1770034418.SGD","LU0540923850.HKD","LU2399975544.HKD","LU0417516571.SGD","02367","LU0348784397.USD","LU0348827113.USD","LU0561508036.HKD","BK1207","02228","BK1197","01530","BK1500","IE00B5MMRT66.SGD","06160","LU1719994722.HKD","IE00BPRC5H50.USD","LU0348766576.USD","LU2476274308.USD","06821","LU1303224171.USD","BK1585","BK1161","LU0348767384.USD","IE00B3M56506.USD","01099","BK1574","09688","LU2328871848.SGD","BK1588","02268","01789","LU1720050803.USD","03933","SG9999014674.SGD","LU0588546209.SGD","601066","LU0348783233.USD","BK1191","LU2476274720.SGD","LU0640798160.USD","LU1969619763.USD","LU0417516902.SGD","09926","BK1141","02196","LU0348735423.USD","BK1515","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111363588","title":"贝莱德增持国药控股H股，持股比例升至9.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111363588","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111363588?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:52","pubTimestamp":1781171542,"startTime":"0","endTime":"0","summary":"根据香港交易所披露的最新权益变动信息，全球资管巨头贝莱德于6月5日增持了国药控股的H股股份。其持有的好仓（长仓）权益比例，已从之前的8.84%显著提升至9.86%。这一变动反映了国际大型投资机构对中国医药流通龙头企业的持续关注与信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099","BK1515","BK1197","BK1500","LU0640798160.USD","LU1115378108.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143121858","title":"贝莱德增持国药控股H股，持股比例从8.74%升至9.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143121858","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143121858?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:17","pubTimestamp":1780996647,"startTime":"0","endTime":"0","summary":"根据香港交易所披露的最新权益信息，全球资管巨头贝莱德对国药控股H股的持股比例出现显著提升。截至6月3日，贝莱德持有的国药控股H股好仓权益比例已增至9.84%，相较于此前披露的8.74%增加了1.1个百分点。贝莱德此番增持，不仅增强了其在该公司的话语权，也可能对其他投资者的决策产生一定的引导效应。后续，市场将密切关注国药控股的经营表现以及主要股东持股结构的进一步变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099","BK1197","LU1115378108.SGD","BK1515","BK1500","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640870152","title":"中信证券资管公司减持国药控股(01099)177.52万股 每股均价约16.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640870152","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640870152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:29","pubTimestamp":1780572543,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月1日，中信证券资产管理有限公司减持国药控股(01099)177.52万股，每股均价16.9396港元，总金额约为3007.12万港元。减持后最新持股数目约为1.46亿股，最新持股比例为10.87%。本次交易涉及其他关联方：中信证券-云帆单一资产管理计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","LU1997245177.USD","LU1328615791.USD","BK0012","06030","BK0028","LU1655091616.SGD","BK1500","BK0188","LU1064131003.USD","LU0405327148.USD","600030","BK0276","LU2148510915.USD","BK1564","LU1997244956.HKD","BK1197","EWH","LU0640798160.USD","BK1515","LU2495084118.USD","LU1064130708.USD","LU2289578879.USD","LU1781817850.SGD","LU1997245094.SGD","BK0183","LU1580142542.USD","BK1147","BK0196","LU0405327494.USD","01099","BK1521","LU1115378108.SGD","LU1794554557.SGD","LU1255011170.USD","BK1516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150690614","title":"国药控股5月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150690614","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150690614?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:36","pubTimestamp":1780562204,"startTime":"0","endTime":"0","summary":"2026年6月4日，国药控股发布2026年5月股份变动月报表。公告显示，公司法定/注册股本为人民币3,120,656,191元，截至5月31日未发生任何增减变动。公司目前的H股为1,341,810,740股，内资股为1,778,845,451股，面值均为1元人民币。报告期内，公司无新增发行、购回、注销或库藏股行为，已发行股份总数较上月底维持不变。公司方面进一步表示，将继续遵守相关上市规则及法律法规的规定，维持股本结构的稳定性和合规性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693461","title":"FMR LLC减持国药控股(01099)约594.78万股 每股作价约17.69港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693461","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638693461?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:26","pubTimestamp":1779971170,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月22日，FMR LLC减持国药控股(01099)594.7847万股，每股作价17.6879港元，总金额约为1.05亿港元。减持后最新持股数目约为1.06亿股，最新持股比例为7.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0640798160.USD","01099","BK1197","BK1515","EWH","LU1115378108.SGD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123457668","title":"国药控股拟回购不超过已发行H股总额10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123457668","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123457668?lang=zh_cn&edition=full","pubTime":"2026-05-28 06:11","pubTimestamp":1779919895,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司近日在公告中披露，公司董事会拟取得一般授权，以在2026年股东周年大会及相关类别股东大会批准后，于授权有效期间回购不超过公司已发行H股总数10%的股份。根据公告，截至2026年5月22日，公司已发行H股约为13.42亿股，若全部行使，该计划的最大回购规模约为1.34亿股。根据公告，股东大会及相关类别股东大会拟于2026年6月18日举行，凡于6月15日名列公司股东名册的股东均有权出席并表决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药控股拟回购不超过已发行H股总额10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638593555","title":"太极集团：下属子公司重庆桐君阁股份有限公司已正式委托给国药控股股份有限公司管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2638593555","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638593555?lang=zh_cn&edition=full","pubTime":"2026-05-25 21:39","pubTimestamp":1779716340,"startTime":"0","endTime":"0","summary":"太极集团在互动平台回答投资者提问时表示，目前，公司下属子公司重庆桐君阁股份有限公司已正式委托给国药控股股份有限公司管理，相关工作均正常开展。后期公司将协同国药集团推进解决同业竞争，相关进展将严格按照《上海证券交易所股票上市规则》的要求进行信息披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605253748490924.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253748490924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","LU0640798160.USD","600129","BK1500","BK1515","BK0113","LU1115378108.SGD","01099","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":0.0425},{"period":"1month","weight":0.1094},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.1117},{"period":"1year","weight":-0.0546},{"period":"ytd","weight":-0.0458}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.1301},{"period":"3month","weight":0.0032},{"period":"6month","weight":-0.0558},{"period":"1year","weight":0.0271},{"period":"ytd","weight":0.0089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004652},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029404},{"month":3,"riseRate":0.470588,"avgChangeRate":0.00701},{"month":4,"riseRate":0.411765,"avgChangeRate":0.016475},{"month":5,"riseRate":0.588235,"avgChangeRate":-0.009205},{"month":6,"riseRate":0.411765,"avgChangeRate":-0.006214},{"month":7,"riseRate":0.529412,"avgChangeRate":-0.007783},{"month":8,"riseRate":0.4375,"avgChangeRate":0.012116},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.01118},{"month":10,"riseRate":0.647059,"avgChangeRate":0.042281},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.00729},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004119}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}